Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Changhoon Yoo
- Target Recruit Count
- 178
- Registration Number
- NCT03524508
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- 1Globe Health Institute LLC
- Target Recruit Count
- 668
- Registration Number
- NCT03522649
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- SuZhou Stainwei Biotech Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03503604
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 92
- Registration Number
- NCT03500874
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03495921
- Locations
- 🇺🇸
Texas Oncology - Pediatrics, Dallas, Texas, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Dana-Farber/Boston Children's Cancer and Blood Disorders, Boston, Massachusetts, United States
A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT03493061
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 146
- Registration Number
- NCT03493048
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT03454620
- Locations
- 🇰🇷
Seoul National Universtiy Hosipital, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Chŏnam, Korea, Republic of
🇰🇷National Cancer Center, Gyeonggi-do, Korea, Republic of
Post Marketing Surveillance Study for ONIVYDE® in South Korea
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 94
- Registration Number
- NCT03446872
- Locations
- 🇰🇷
Konyang University Hospital, Daejeon, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷ASAN Medical Center, Seoul, Korea, Republic of
SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 130
- Registration Number
- NCT03443492
- Locations
- 🇨🇳
National Institute of Cancer Research, Miaoli, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.